Literature DB >> 17662376

Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.

Maurie Markman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17662376     DOI： 10.1016/j.ygyno.2007.06.005

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


× No keyword cloud information.
  4 in total

Review 1.  Pharmaceutical management of ovarian cancer : current status.

Authors:  Maurie Markman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

2.  A systematic model specification procedure for an illness-death model without recovery.

Authors:  Christine Eulenburg; Sven Mahner; Linn Woelber; Karl Wegscheider
Journal:  PLoS One       Date:  2015-04-13       Impact factor: 3.240

Review 3.  CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.

Authors:  Danny W K Lum; Pablo Perel; Aroon D Hingorani; Michael V Holmes
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

4.  Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany.

Authors:  Inna Dabisch; Jürgen Dethling; Charalabos-Markos Dintsios; Melanie Drechsler; Daniel Kalanovic; Peter Kaskel; Frank Langer; Jörg Ruof; Thorsten Ruppert; Daniel Wirth
Journal:  Health Econ Rev       Date:  2014-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.